Praxis Releases Results from Essential1 Clinical Trial
Earlier this spring, Praxis Precision Medicines reported topline results from its Phase 2 Essential1 clinical study of ulixacaltamide (formerly PRAX-944) to treat essential tremor (ET). The IETF’s newest ET Virtual Education Event, “Dare for More in ET: Ulixacaltamide Study Findings,” focuses on results from this Phase 2 trial and what they mean for people living with ET.
Ulixacaltamide was developed with essential tremor in mind. It was designed to block T-type calcium channels in certain parts of the brain to help stop tremors and improve function. The study found participants taking ulixacaltamide scored better than placebo on nearly all the ADL measures (10 of 12, including dressing, using keys, pouring, writing, drinking, among others.) Additionally, participants and their doctors reported overall improvement with ulixacaltamide versus placebo, and it was generally well-tolerated.
As a next step, Praxis will be meeting with the Food and Drug Administration (FDA) in June to discuss the results and receive feedback on its plans for a Phase 3 trial to support a marketing application for ulixacaltamide.
Miss New Hampshire Contestant is Raising ET Awareness
Jillian Mars was 15 when she first noticed her essential tremor (ET). But it took her seven years to get a diagnosis. There’s still a perception that ET only impacts older adults, but she’s working to change all that.
Jillian has adopted essential tremor as her community service initiative as she participates in pageants through the Miss New Hampshire Scholarship Program. She talks about her work in our latest Talking Essential Tremor podcast, “Spreading ET Awareness through the Miss New Hampshire Scholarship Pageant.”
“It’s been incredible getting to speak to my communities about essential tremor,” she said.
Her pageant work has earned Jillian $5,000 in scholarships so far. She also received a college scholarship from the IETF in the spring of 2023.
What’s her advice for young people who have ET?
“It’s nothing to be afraid of or ashamed of,” she said. “There’s no reason why my body shaking should embarrass me.”
Remember a Loved One with a Memorial Donation
Memorial Day is a national day of mourning designed to honor military personnel who sacrificed their lives while serving in the armed forces. Over the years, it also has become a day to honor family and friends who have died.
As Memorial Day approaches, consider honoring a loved one with a memorial contribution to the IETF. There is no set minimum contribution and all memorials are posted on the IETF website and in Tremor Talk magazine.
We often see memorial contributions this time of year and also around birthdays and anniversaries of loved ones.
As with all donations to the IETF, memorial donations are tax-deductible.
Clinical Trials Need You!
If you want to make a difference in the search for better treatments for essential tremor, consider participating in a clinical trial. On our website, we keep an ongoing list of clinical trials recruiting participants. Here are some of the most recent ones:
· Researchers in the Voice Lab at The University of Texas at Austin invite individuals with essential tremor to participate in a study of voice. The goals of the study are to understand how speakers control their voice and to develop therapy that improves vocal control. For more information contact the UT Voice Lab, (512) 232-4428, or email firstname.lastname@example.org.
· Jazz Pharmaceuticals’ EveresT Study is a research study testing the safety and effectiveness of an investigational medication that may help decrease tremor severity for people diagnosed with essential tremor (ET). To learn more and sign up for the study, please visit the study website here.
· The KINETIC 2 TRIAL is evaluating the safety and efficacy of three different doses of an investigational drug compared to a placebo on reducing tremors in adults diagnosed with essential tremor. Participation lasts approximately 19 weeks. Visit the study website at KINETIC2ETtrial.com to learn more.